Saturday 17 October 2026
Export DNTH’s income statement to Excel — free account
Dianthus Therapeutics, Inc.
DNTH Healthcare Biotechnology
Dianthus Therapeutics, Inc.’s revenue for fiscal 2025 (year ended December 2025) was $2.0 million, down 67.3% from fiscal 2024. In the quarter to June 2026, revenue grew 294.3%, EPS fell 2.27% and free cash flow fell 105.4%, each against the same quarter a year earlier.
72.09
2.44
−3.27%
Follow DNTH
| Jun '26 | Mar '26 | Dec '25 | Sep '25 | Older periods | |
|---|---|---|---|---|---|
P/E ratio |
0.00 | 0.00 | 0.00 | 0.00 |
+8 more quarters Free account |
P/S ratio |
2,868.55 | 3,017.14 | 781.65 | 483.17 | |
P/FCF ratio |
0.00 | 0.00 | 0.00 | 0.00 | |
P/Operating CF |
(111.51) | (139.69) | (33.87) | (48.67) | |
P/B ratio |
4.66 | 3.36 | 3.23 | 2.72 | |
Price to Tangible BV |
4.66 | 3.36 | 3.23 | 2.72 | |
EV/Sales |
2,402.79 | 2,185.36 | 583.07 | 352.37 | |
EV/EBITDA |
0.00 | 0.00 | 0.00 | 0.00 | |
EV/Operating CF |
(29.44) | (22.41) | (9.20) | (9.90) | |
EV/FCF |
(29.38) | (22.38) | (9.18) | (9.89) | |
Quick Ratio |
25.79 | 29.06 | 13.16 | 17.09 | |
Current Ratio |
26.10 | 29.25 | 13.32 | 17.35 | |
Net Debt/EBITDA |
13.23 | 23.31 | 5.75 | 9.47 | |
Debt/Assets |
0.00% | 0.00% | 0.00% | 0.00% | |
Debt/Equity |
0.00 | 0.00 | 0.00 | 0.00 | |
Asset Turnover |
0.00 | 0.00 | 0.00 | 0.01 | |
Operating CF/Net income |
0.98 | 0.71 | 0.73 | 0.83 | |
Capex/Depreciation |
0.03 | 0.01 | 0.18 | 0.00 | |
Research and Development Expense of Revenue |
6,397.63% | 7,457.45% | 21,089.79% | 8,204.29% | |
Selling, General and Administrative Expense of Revenue |
1,781.47% | 2,692.87% | 3,496.48% | 2,069.44% | |
Intangible Assets out of Total Assets |
0.00 | 0.00 | 0.00 | 0.00 | |
Share Based Compensation of Revenue |
1,563.47% | 2,289.85% | 2,104.93% | 1,463.13% | |
Graham Net Nets |
0.16 | 0.27 | 0.23 | 0.26 | |
Graham Number |
0.00 | 0.00 | 0.00 | 0.00 | |
Earnings Yield |
(4.26%) | (4.92%) | (9.95%) | (8.84%) | |
Free Cash Flow Yield |
(2.85%) | (3.24%) | (8.12%) | (7.37%) | |
Revenue per Share |
0.01 | 0.01 | 0.01 | 0.01 | |
Operating CF per Share |
(0.87) | (0.60) | (1.22) | (0.81) | |
Capex per Share |
0.00 | 0.00 | 0.00 | 0.00 | |
Free Cash Flow per Share |
(0.88) | (0.60) | (1.22) | (0.81) | |
Cash per Share |
15.83 | 23.14 | 10.47 | 10.65 | |
Shareholders Equity per Share |
20.92 | 25.01 | 12.78 | 14.46 | |
Interest Debt per Share |
0.00 | 0.00 | 0.00 | 0.00 | |
Book value per Share |
20.92 | 25.01 | 12.78 | 14.46 | |
Free Cash Flow |
(49.16) | (28.87) | (47.12) | (30.56) | |
Working Capital |
863.15 | 1,081.63 | 378.71 | 389.97 | |
Capital Expenditures |
(0.18) | (0.01) | (0.14) | 0.00 | |
Net Current Asset Value |
856.29 | 1,074.34 | 371.92 | 382.83 | |
EV/EBIT |
0.00 | 0.00 | 0.00 | 0.00 | |
Capex to Sales |
0.24 | 0.02 | 0.49 | 0.01 | |
Price to Operating Income |
0.00 | 0.00 | 0.00 | 0.00 | |
| Other line items | |||||
Average Receivables |
0.07 | 1.12 | 0.43 | 3.84 | |
Average Payables |
5.90 | 6.77 | 7.15 | 7.14 | |
Average Assets |
769.67 | 797.73 | 452.47 | 465.85 | |
Average Common Equity |
737.55 | 764.96 | 422.94 | 442.18 |
Columns are period end dates